Sep 10, 2024, 04:33
Elias Karam: ACCENT pooled analysis published in JCO
Elias Karam,
Auhtors: Benoist Chibaudel, Morteza Raeisi, Romain Cohen, Greg Yothers, Richard M. Goldberg, Jean-Baptiste Bachet, Norman Wolmark, Takayuki Yoshino, Hans-Joachim Schmoll, Rachel Kerr, Sara Lonardi, Thomas J. George, Einat Shacham-Shmueli, Qian Shi, Thierry André, Aimery de Gramont.
“ACCENT pooled analysis published in JCO:
No benefit of OX was observed for OS in either the low-risk or even in high-risk patient subgroup, stage II colon cancer
OX should not be anymore our standard of care even in high risk stage II colon cancer population.
FP (CAPE or 5-FU) does the job.”
Source: Elias Karam/LinkedIn
Aimery de Gramont
Benoist Chibaudel
cancer
Colon cancer
Einat Shacham-Shmueli
Elias Karam
Greg Yothers
Hans-Joachim Schmoll
Jean-Baptiste Bachet
Journal of Clinic Oncology
Morteza Raeisi
Norman Wolmark
OncoDaily
Oncology
Qian Shi
Rachel Kerr
Richard M. Goldberg
Romain Cohen
Sara Lonardi
Takayuki Yoshino
Thierry Andre
Thomas J. George
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54